How many times can a box of Avatrombopag (Sucoxin) be taken and dosage analysis

Avatrombopag is an oral thrombopoietin receptor agonist, mainly used to treat thrombocytopenia in patients with chronic liver disease before elective surgery, and in patients with chronic immune thrombocytopenia (ITP). The drug stimulates the proliferation and differentiation of megakaryocytes in the bone marrow, thereby promoting platelet production and helping patients restore safe platelet levels. The dosage and course of treatment vary depending on the type of disease, patient weight, baseline platelet value, and treatment purpose. Therefore, the physician's individual guidance must be followed in actual use.

Taking patients with chronic liver disease as an example, the recommended dose of avatrombopag is usually 40mg or 60mg daily for 5 days. The specific dose depends on the preoperative baseline platelet level: if it is lower than 40 If between pan>40–50 Patients usually start taking medication 10 to 13 days before planned surgery and continue to take it The medication will be stopped after 5 days, and the surgery will be performed within 5 to 8 days after the last dose. Calculated according to this plan, a box of avatrombopag usually contains 10 tablets (each 20mg), which can be taken from 1box to 1.5boxes for one course of treatment, depending on the prescribed dose.

For patients with chronic immune thrombocytopenia (ITP), the starting dose of avatrombopag is usually 20 mg once daily orally once daily, with the dose adjusted as needed to maintain platelet maintenance The level is 50–150×10⁹/Lbetween. If the platelet level does not reach the target level, the dose can be gradually increased to 40 mg or 60 mg per day; otherwise, if the platelet level is too high, the dose can be reduced or the dosage can be interrupted. Most of these patients are on long-term or intermittent treatment, so one box of medicine can be used for 5 days to 10 days, and the dosage cycle needs to be flexibly adjusted according to the platelet monitoring results.

In general, the dosage design of avatrombopag is highly individualized. The length of treatment and dosage requirements depend on the patient's specific condition and treatment goals. Throughout the medication period, patients should regularly check their platelet levels to avoid excessive elevations that may lead to the risk of blood clots. Doctors usually dynamically adjust dosages based on monitoring results to ensure efficacy and safety. Patients should not increase or decrease the dosage or extend the course of treatment on their own. Only by taking it strictly according to the doctor's instructions can the platelet count be effectively increased in the short term and the risk of preoperative or bleeding-related complications be reduced.

Reference materials:https://www.drugs.com/